Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...

The anticancer potency of Camptotheca acuminata is attributed to camptothecin (CPT), an alkaloid scientists have isolated from the tree's bark and stems. Research revealed that this compound ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Lilly is paying $13 million upfront for exclusive rights to use ImmunoGen's novel camptothecin molecules in ADCs against drug a first batch of drug targets, with an option on a second batch that ...